Draft Guidance on Lithium Carbonate

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Lithium Carbonate
Form/Route: Capsules/Oral
Recommended studies: 1 study

Type of study: Fasting
Design: Single-dose, two way crossover \textit{in-vivo}
Strength: 600 mg
Subjects: Normal healthy males and females, general population
Additional comments: Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.

Analytes to measure (in appropriate biological fluid): Lithium in plasma

Bioequivalence based on (90\% CI): Lithium

Waiver request of \textit{in-vivo} testing: 150 mg and 300 mg based on (i) acceptable bioequivalence studies on the 600 mg strength, (ii) proportionally similar across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a \textbf{Dissolution Methods Database} is available to the public at the OGD website at \url{http://www.fda.gov/cder/ogd/index.htm}. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Jul 2008